Company news

Mesoblast Limited news in 2026

Mesoblast Limited's news releases, calls and decks from 2026, newest first.

View company

Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

March 11, 2026

Ryoncil Profits Underpinning Substantial Growth Pipeline

February 26, 2026

Corporate Presentation and Half Year Financial Results

February 26, 2026

Half Year Report and Accounts (including Appendix 4D)

February 26, 2026

Ryoncil® Profits Underpinning Substantial Growth Pipeline

February 26, 2026

High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD

February 11, 2026

Quarterly Activities/Appendix 4C Cash Flow Report

January 28, 2026

Ryoncil® Net Revenues Increase for the Quarter to US$30M

January 28, 2026

Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment

January 26, 2026

FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy

January 17, 2026

Ryoncil Sales for the Quarter Increase 60% to US$35.1M

January 8, 2026

Ryoncil® Sales Increase 60% in December Quarter to US$35.1M

January 8, 2026

Mesoblast Announces Changes to Board of Directors' Leadership Roles

January 1, 2026

← Newer news releases

Calls in 2026

Decks in 2026